Home > Insider Trading > Filing (0001181431-12-014968)

Filing Details

Accession Number:: 0001181431-12-014968
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-03-06 19:53:00
Reporting Period:: 2012-03-02

Filing Date:: 2012-03-06
Accepted Time:: 2012-03-06 19:53:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131907	Micromet Inc.	MITI	Biological Products, (No Disgnostic Substances) (2836)	522243564

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
318154	Amgen Inc	One Amgen Center Drive Thousand Oaks CA 91320-1799		No	No	Yes	No
1543400	Armstrong Acquisition Corp.	C/O Amgen Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-03-02	452,388	$11.00	80,477,485	No	4	P	Indirect	By Armstrong Acquisition Corp.
Common Stock	Acquisiton	2012-03-05	2,035,994	$11.00	82,513,479	No	4	P	Indirect	By Armstrong Acquisition Corp.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Armstrong Acquisition Corp.
No	4	P	Indirect	By Armstrong Acquisition Corp.

Footnotes

The initial tender offer (the "Initial Offer") commenced by Armstrong Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"), to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the "Shares") of Micromet, Inc. ("Micromet") at a purchase price of $11.00 per Share in cash (the "Offer Price") expired at 12:00 midnight, New York City time, at the end of Thursday, March 1, 2012 (the "Expiration Date"). Based on the information provided to Amgen by the depositary for the tender offers (the "Depositary") on March 2, 2012, approximately 452,388 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, dated February 2, 2012 (the "Offer to Purchase"), had been validly tendered and accepted for payment.
Following the Expiration Date, the Purchaser commenced a subsequent offering period (the "Subsequent Offer") to acquire all of the remaining untendered Shares of Micromet. The Subsequent Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of March 6, 2012. Shares validly tendered during this Subsequent Offer are accepted immediately for payment and tendering stockholders are paid the Offer Price, upon the same terms and subject to the same conditions as the Initial Offer, as set forth in the Offer to Purchase and the related Letter of Transmittal included as exhibits to the Tender Offer Statement on Schedule TO-T filed by Purchaser and Amgen with the Securities and Exchange Commission on February 2, 2012, except that Shares tendered during the Subsequent Offer may not be withdrawn.
Based on the information provided to Amgen by the Depositary on March 5, 2012, approximately 349,177 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, had been validly tendered and accepted for payment and approximately 1,686,817 Shares had been validly tendered and accepted for payment in the Subsequent Offer.